Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

Immunotherapy

Volumn 8, Issue 2, 2016, Pages 135-143

  George, Binsah ^a   Kantarjian, Hagop ^a   Jabbour, Elias ^a   Jain, Nitin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute lymphoblastic leukemia; antibody drug conjugate; inotuzumab; monoclonal antibody

Indexed keywords

INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ALLOGRAFT; PHASE 2 CLINICAL TRIAL (TOPIC); PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION;

ALLOGRAFTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION;

EID: 84956957250     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.108     Document Type: Article

References (48)

1. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: Insights and treatment implications. Nat. Rev. Clin. Oncol. 12(6), 344-357 (2015).
2. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the cancer and leukemia group B. Hematol. Oncol. Clin. North Am. 14(6), 1367-1379, x (2000).
3. Kantarjian H, Thomas D, O'Brien S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12), 2788-2801 (2004).
4. Gokbuget N, Hoelzer D, Arnold R et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol. Oncol. Clin. North Am. 14(6), 1307-1325, ix (2000).
5. Fielding AK, Richards SM, Chopra R et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3), 944-950 (2007).
6. Faderl S, Thomas DA, O'Brien S et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin. Lymphoma Myeloma Leuk. 11(1), 54-59 (2011).
7. Thomas DA, Faderl S, Cortes J et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12), 4396-4407 (2004).
8. Ravandi F, O'Brien S, Thomas D et al. First report of Phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomepositive (Ph+) acute lymphoblastic leukemia. Blood 116(12), 2070-2077 (2010).
9. Bassan R, Rossi G, Pogliani EM et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: northern Italy Leukemia Group protocol 09/00. J. Clin. Oncol. 28(22), 3644-3652 (2010).
10. Thomas DA, Faderl S, O'Brien S et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7), 1569-1580 (2006).
11. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: A new dawn in the treatment of acute lymphoblastic leukemia. J. Clin. Oncol. 30(31), 3876-3883 (2012).
12. Raponi S, De Propris MS, Intoppa S et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases. Leuk. Lymphoma 52(6), 1098-1107 (2011).
13. DiJoseph JF, Armellino DC, Boghaert ER et al. Antibodytargeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5), 1807-1814 (2004).
14. Piccaluga PP, Arpinati M, Candoni A et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. Lymphoma 52(2), 325-327 (2011).
15. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230(1), 128-143 (2009).
16. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol. 15, 481-504 (1997).
17. Sullivan-Chang L, O'donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. Biodrugs 27(4), 293-304 (2013).
18. Hursey M, Newton DL, Hansen HJ et al. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics. Leuk. Lymphoma 43(5), 953-959 (2002).
19. Daridon C, Blassfeld D, Reiter K et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res. Ther. 12(6), R204 (2010).
20. De Vries JF, Zwaan CM, De Bie M et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26(2), 255-264 (2012).
21. Moyron-Quiroz JE, Partida-Sanchez S, Donis-Hernandez R, Sandoval-Montes C, Santos-Argumedo L. Expression and function of CD22, a B-cell restricted molecule. Scand. J. Immunol. 55(4), 343-351 (2002).
22. Hanna R, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res. 56(13), 3062-3068 (1996).
23. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21(11), 2240-2245 (2007).
24. Dijoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother. Pharmacol. 67(4), 741-749 (2011).
25. Dijoseph JF, Dougher MM, Kalyandrug LB et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer. Res. 12(1), 242-249 (2006).
26. Dijoseph JF, Goad ME, Dougher MM et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer. Res. 10(24), 8620-8629 (2004).
27. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer. Res. 17(20), 6417-6427 (2011).
28. Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur. J. Haematol. 94(2), 99-108 (2015).
29. Zein N, Sinha AM, Mcgahren WJ, Ellestad GA. Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240(4856), 1198-1201 (1988).
30. Thomas X. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin. Invest. Drugs 21(6), 871-878 (2012).
31. John B, Herrin BR, Raman C et al. The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J. Immunol. 170(7), 3534-3543 (2003).
32. Portell CA, Advani AS. Novel targeted therapies in acute lymphoblastic leukemia. Leuk. Lymphoma 55(4), 737-748 (2014).
33. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 30(5), 625-639 (2013).
34. Van Der Velden VH, Te Marvelde JG, Hoogeveen PG et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10), 3197-3204 (2001).
35. Van Der Velden VH, Boeckx N, Jedema I et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18(5), 983-988 (2004).
36. Ohanian M, Kantarjian H, Guy D et al. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin. Biol. Ther. 15(4), 601-611 (2015).
37. Ravandi F, Estey EH, Appelbaum FR et al. Gemtuzumab ozogamicin: time to resurrect? J. Clin. Oncol. 30(32), 3921-3923 (2012).
38. Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol. Immunol. 67(2), 107-116 (2014).
39. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J. Clin. Oncol. 29(5), 532-543 (2011).
40. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a Phase I study. J. Clin. Oncol. 28(12), 2085-2093 (2010).
41. Kantarjian H, Thomas D, Jorgensen J et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15), 2728-2736 (2013).
42. Kantarjian H, Thomas D, Jorgensen J et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A Phase 2 study. Lancet Oncol. 13(4), 403-411 (2012).
43. Jain N, O'Brien S, Thomas D, Kantarjian H. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Front. Biosci. (Elite Edition) 6, 40-45 (2014).
44. Kebriaei P, Wilhelm K, Ravandi F et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin. Lymphoma Myeloma Leuk. 13(3), 296-301 (2013).
45. Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 61(2), 369-372 (2014).
46. Jabbour E, O'Brien S, Huang X et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am. J. Hematol. 90(3), 193-196 (2015).
47. Deangelo DJ, Stock W, Shustov AR et al. Weekly inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). Blood 122(21), 3906a (2013).
48. Jabbour E, O'Brien S, Thomas DA et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients (= 60 years) with acute lymphoblastic. Leukemia 124(21), a794 (2014).